OCA
LXEO icon

Octagon Capital Advisors’s Lexeo Therapeutics LXEO Stock Holding History

Octagon Capital Advisors’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,100,000
Closed -$6.31M – 31
2026
Q1 		$6.31M Sell
1,100,000
-625,000
-36% -$4.43M 0.7% 25
2025
Q4 		$17.1M Buy
+1,725,000
New +$15.7M 2.08% 20

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Octagon Capital Advisors's LXEO Position: Q2 2026 in Review

Octagon Capital Advisors sold out of Lexeo Therapeutics (LXEO) in Q2 2026, closing a stake of 1,100,000 shares — an estimated $6.31M sold.

Octagon Capital Advisors first reported a position in LXEO in Q4 2025 and held it in 2 quarters. The position peaked at $17.1M in Q4 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Octagon Capital Advisors reported no remaining Lexeo Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Octagon Capital Advisors sold 1,100,000 Lexeo Therapeutics shares in Q2 2026, an estimated $6.31M.
  • Octagon Capital Advisors first reported a position in Lexeo Therapeutics in Q4 2025 and held it in 2 quarters.
  • Octagon Capital Advisors's Lexeo Therapeutics position peaked at $17.1M in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.